<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Sanofi-Aventis</title>
	<atom:link href="http://www.stockbloghub.com/tag/sanofi-aventis/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Active on the Generics Front</title>
		<link>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937</link>
		<comments>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937#comments</comments>
		<pubDate>Mon, 09 Apr 2012 18:03:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97937</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s generic versions of Sanofi’s (SNY) high blood pressure drugs, Avapro and Avalide, AstraZeneca’s (AZN) schizophrenia treatment, Seroquel, and Forest Laboratories’ (FRX) Lexapro. While Teva will enjoy a 180-day period of marketing exclusivity where the generic launches of Avapro, Avalide and Lexapro are concerned, we note that other generic players like Dr. Reddy’s Laboratories (RDY) and Mylan (MYL) have also launched their generic versions of Seroquel. As per IMS data, annual US sales of Avapro, Avalide, Seroquel, and Lexapro were $464 million, $124 million, $4.6 billion and $2.9 billion, respectively. Teva also launched its authorized generic of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Analyst Maintains Neutral Share rating</title>
		<link>http://www.stockbloghub.com/2012/02/24/prgo-perrigo-analyst-maintains-neutral-share-rating/92526</link>
		<comments>http://www.stockbloghub.com/2012/02/24/prgo-perrigo-analyst-maintains-neutral-share-rating/92526#comments</comments>
		<pubDate>Fri, 24 Feb 2012 18:21:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=92526</guid>
		<description><![CDATA[We have maintained our Neutral rating on Perrigo Company (PRGO) with a target price of $100.00 following appraisal of second quarter of fiscal 2012 results. Perrigo reported second quarter EPS of $1.20, beating the Zacks Consensus Estimate of $1.16 and the year-earlier earnings of $1.05 per share. A robust top-line performance boosted earnings in the quarter. Strong performance by Rx Pharmaceuticals and new products led to the sales growth. Perrigo is a dominant player in the store brand over the counter (OTC) drug market. We believe that Perrigo’s strong position in the brand OTC pharmaceutical market and growing generics and API businesses will help it deliver solid top- and bottom-line growth in the coming years. In the OTC pharmaceutical market, products are sold due to changes in product status from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/24/prgo-perrigo-analyst-maintains-neutral-share-rating/92526/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Analyst Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609</link>
		<comments>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609#comments</comments>
		<pubDate>Sat, 21 Jan 2012 20:38:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90609</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex, posted sales of $2,518.4 million, up 8.4%, in 2010. We expect Avonex to continue contributing significantly to the top-line thanks to price increases, focused marketing effort, expansion into new markets and positive clinical data. Meanwhile, Tysabri, the company’s second MS product, continues to see an increase in patients despite carrying a “black box” warning for the risk of progressive multifocal leukoencephalopathy (PML) and other cautionary language. Tysabri posted $1.2 billion in sales in 2010. Tysabri’s launch in new markets like India, Brazil, Argentina, the Middle East and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma  Drug Earns Priority Review</title>
		<link>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265</link>
		<comments>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265#comments</comments>
		<pubDate>Mon, 16 Jan 2012 23:37:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90265</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the Canadian regulatory body has granted priority review status to the company’s new drug submission (NDS) for Cinryze. ViroPharma is seeking the drug’s approval for the treatment of prevention, pre-procedure prevention, and treatment of attacks of hereditary angioedema (HAE) in patients who are six years or older. The company expects Health Canada to complete its review of Cinryze in the second half of 2012. We note that Cinryze is currently marketed in the US for the prevention of angioedema attacks in adolescent and adult patients with HAE. In the European Union (EU), the same drug is marketed for the treatment of prevention, pre-procedure prevention, and treatment of attacks of HAE in adolescents and adult patients. We view this development as a positive for ViroPharma, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals</title>
		<link>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883</link>
		<comments>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:34:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89883</guid>
		<description><![CDATA[The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&#38;A) deals have taken place in the pharma sector over the last couple of years. With most of the big pharma players already facing or likely to face generic threats to their key products, the companies are resorting to M&#38;As and in-licensing deals to counter the loss of revenues that will arise following the genericization of its key drugs. Pharma major Bristol-Myers is no exception as the generic threat looms over many of its key drugs, including the blockbuster blood-thinner Plavix, co-developed with Sanofi (SNY). Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions, and is introducing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Sees Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2011/12/24/bmy-bristol-myers-squibb-sees-pipeline-setback/89198</link>
		<comments>http://www.stockbloghub.com/2011/12/24/bmy-bristol-myers-squibb-sees-pipeline-setback/89198#comments</comments>
		<pubDate>Sat, 24 Dec 2011 15:13:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[BSC]]></category>
		<category><![CDATA[ELEMENTS BG Small Cap ETN]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89198</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback with its oncology candidate, brivanib, performing disappointingly in a late-stage study (BRISK-PS). The study evaluated brivanib as a combination therapy in liver cancer patients who had either failed or were intolerant to Onyx Pharmaceuticals, Inc. / Bayer’s (ONXX/BAYRY) Nexavar. Results from the multicenter, double-blind, randomized study revealed that there was no improvement in the overall survival rate for patients treated with brivanib and the best supportive care (BSC) versus those in the placebo plus BSC arm. Bristol-Myers intends to present detailed data from the study at an upcoming scientific conference. The disappointing results of the BRISK-PS study notwithstanding, Bristol-Myers intends to continue evaluating the liver cancer candidate in three other late-stage studies. Bristol-Myers stated that it has conducted 29 studies till ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/24/bmy-bristol-myers-squibb-sees-pipeline-setback/89198/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Reports Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2011/12/14/bmrn-biomarin-pharmaceutical-reports-pipeline-progress/87928</link>
		<comments>http://www.stockbloghub.com/2011/12/14/bmrn-biomarin-pharmaceutical-reports-pipeline-progress/87928#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:17:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87928</guid>
		<description><![CDATA[Recently, BioMarin Pharmaceutical Inc. (BMRN) commenced a mid-stage study of its pipeline candidate GALNS (N-acetylgalactosamine 6-sulfatase) in children suffering from mucopolysaccharidosis IVA (MPS IVA), a rare genetic enzyme deficiency disorder. The company intends to evaluate the safety and tolerability of the drug dosed at 2.0 mg/kg/week over a period of one year. The study will evaluate 10 to 15 children below 5 years of age. The open-label, multinational study will also evaluate the levels of urinary keratan sulfate (KS) and growth velocity. Apart from the mid-stage study in children, GALNS is also being evaluated in a randomized, double-blind, placebo-controlled late-stage study (n~160) in the MPS IVA indication. BioMarin is enrolling patients in a late stage study with primary endpoint of six-minute walk distance. Enrollment is underway in the 24-week study. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/bmrn-biomarin-pharmaceutical-reports-pipeline-progress/87928/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278</link>
		<comments>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278#comments</comments>
		<pubDate>Fri, 09 Dec 2011 17:40:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88278</guid>
		<description><![CDATA[We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results. Micromet’s third quarter 2011 loss per share came in at 21 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 13 cents per share (also adjusting for the change in fair value of warrants). Lower-than-expected revenues led to the wider loss in the quarter. Revenues at Micromet were down almost 33% from the prior-year period to $4.5 million in the third quarter of 2011 due to lower collaboration revenue. Moreover, revenues in the year-ago quarter were boosted by the presence of a milestone payment from AstraZeneca (AZN). Revenues were also much below the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Begins New Trial</title>
		<link>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072</link>
		<comments>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072#comments</comments>
		<pubDate>Tue, 06 Dec 2011 19:36:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88072</guid>
		<description><![CDATA[Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL). The trial was advised to be conducted by the US Food &#38; Drug Administration (FDA) to support accelerated approval of blinatumomab. The trial is a single-arm study which will evaluate 65 patients with the primary endpoint of complete remission (CR) or CR with partial recovery of blood counts (CRh). Micromet expects to complete enrollment for the trial by year-end 2012. The mid-stage study will be followed by a late-stage trial (with a time dependent endpoint) to evaluate the safety and efficacy of blinatumomab versus chemotherapy in adult patients with relapsed refractory B precursor ALL. Design details of the late-stage trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Analyst Downgrades Shares to Neutral</title>
		<link>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746</link>
		<comments>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746#comments</comments>
		<pubDate>Wed, 30 Nov 2011 18:51:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87746</guid>
		<description><![CDATA[We recently downgraded Isis Pharmaceuticals (ISIS) to Neutral from an Outperform recommendation. Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies, such as antisense. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments, and royalties. Isis Pharma’s lead pipeline candidate, Kynamro (mipomersen), is being developed for the treatment of familial hypercholesterolemia (FH). Isis Pharma has a collaboration agreement with Genzyme, a subsidiary of Sanofi-Aventis (SNY) for Kynamro. While the companies filed for EU approval of Kynamro in July, the US filing is scheduled to take place later this month. Acceptance of the US filing will trigger a $25 million milestone payment from Sanofi, most likely in early 2012. Isis Pharma and Sanofi ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Beats Earnings Forecast &#8211; Sales Miss</title>
		<link>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198</link>
		<comments>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:04:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86198</guid>
		<description><![CDATA[Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales performance was offset by a lower tax rate to drive earnings growth. First quarter revenues increased approximately 13% over the prior year to $725.3 million. Total revenues were, however, below the Zacks Consensus Estimate of $748 million. Strong performances by the Active Pharmaceutical Ingredients (API) and Rx Pharmaceuticals segments were offset by sluggish revenues from the company’s Nutritional and Consumer Healthcare businesses due to competitive pressures. The First Quarter of Fiscal 2012 in Detail The revenue performance in the quarter from four of the company’s businesses is detailed below. Consumer Healthcare (CHC): Perrigo reported CHC revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Posts Lower Loss</title>
		<link>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689</link>
		<comments>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689#comments</comments>
		<pubDate>Tue, 25 Oct 2011 17:38:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[iShares S&P Target Date 2010]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NICE Systems Limited]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TZD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85689</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher revenues and lower expenses led to the lower year-over-year loss. Third quarter revenues, which included a $15 million milestone payment, increased 12.1% to $175 million. Revenues exceeded the Zacks Consensus Estimate of $166 million. Quarterly Details Quarterly revenues consisted of $155.1 million in product sales (up 0.7%) and $19.9 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Collaborative revenues included a $15 million milestone payment from Lilly on the launch of Bydureon in the EU. Collaborative ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960</link>
		<comments>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960#comments</comments>
		<pubDate>Sat, 24 Sep 2011 18:58:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MNTA]]></category>
		<category><![CDATA[Momenta Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83960</guid>
		<description><![CDATA[Momenta Pharmaceuticals, Inc. (MNTA) and Novartis AG (NVS) filed a lawsuit against Amphastar Pharmaceuticals, Inc. and Watson Pharmaceuticals Inc. (WPI) regarding the generic version of Sanofi-Aventis’ (SNY) Lovenox. The lawsuit was filed in United States District Court for the District of Massachusetts. The lawsuit claims that Amphastar Pharma&#8217;s generic Lovenox, which was approved by the US Food and Administration (FDA) on September 19, infringes two of Momenta&#8217;s US patents. Amphastar Pharma plans to launch generic Lovenox in the US in the fourth quarter of 2011. Lovenox is indicated for the prophylaxis and treatment of deep vein thrombosis and prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction. According to IMS Health, US sales of Lovenox and its generic equivalents amounted to about $2.6 billion for the twelve months ended ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/24/mnta-momenta-pharmaceuticals-and-novartis-ag-sue-watson-pharmaceuticals/83960/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Presents HCV Data</title>
		<link>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567</link>
		<comments>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:50:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83567</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) presented encouraging data from a phase II study (n=48) which evaluated its candidate BMS-790052 in combination with peginterferon and ribavirin (standards of care) for treating patients suffering from the hepatitis C virus (HCV). Bristol-Myers presented data from the mid-stage study at the 51st interscience conference on antimicrobial agents and chemotherapy held in the US. The double-blind study evaluated BMS-790052 at three doses (3 mg, 10 mg or 60 mg) in treatment-naïve patients infected with genotype 1 chronic HCV. Results from the study revealed that the rate of SVR24 (sustained virologic response – absence of detectable HCV at 24 weeks post treatment ) achieved by patients treated with a combination of BMS-790052, PEG-interferon alfa and ribavirin was higher across all evaluated doses than those receiving placebo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Brilinta Now in US</title>
		<link>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949</link>
		<comments>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:47:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81949</guid>
		<description><![CDATA[AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS). Following the launch, AstraZeneca plans to work with distribution partners and pharmacy customers to ensure that Brilinta is readily available for use. The regulatory body’s approval was based on the PLATO study, which compared Brilinta to clopidogrel in 18,624 patients suffering from ACS. The study demonstrated that there was no statistical difference in adverse reactions observed among patients treated with Brilinta, compared to those treated with clopidogrel. Clopidogrel, which is marketed worldwide by Bristol-Myers Squibb &#38; Co. (BMY) and Sanofi-Aventis (SNY) under the brand name Plavix, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Get Encouraging Data</title>
		<link>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258</link>
		<comments>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258#comments</comments>
		<pubDate>Wed, 14 Sep 2011 16:41:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82258</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner Eliquis (apixaban) in patients suffering from erratic heartbeat and carrying at least one additional risk factor for stroke. The cardiac rhythm disorder is referred to as atrial fibrillation (AF). Bristol-Myers and Pfizer presented detailed data from the study at the European Society of Cardiology. Topline results were presented in June 2011. Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US. Data from the randomized, double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin in reducing the risk of stroke or systemic embolism. Patients treated with Eliquis were 21% less likely ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAC) Company News for September 12, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/09/12/bac-company-news-for-september-12-2011-corporate-summary/82981</link>
		<comments>http://www.stockbloghub.com/2011/09/12/bac-company-news-for-september-12-2011-corporate-summary/82981#comments</comments>
		<pubDate>Mon, 12 Sep 2011 17:14:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Money Center Banks]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[JEF]]></category>
		<category><![CDATA[Jefferies Group Inc.]]></category>
		<category><![CDATA[KR]]></category>
		<category><![CDATA[Kroger Company]]></category>
		<category><![CDATA[LAZ]]></category>
		<category><![CDATA[Lazard Limited]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Research In Motion Limited]]></category>
		<category><![CDATA[RIMM]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ULTA]]></category>
		<category><![CDATA[Ulta Salon Cosmetics & Fragrance Inc]]></category>
		<category><![CDATA[VeriSign Inc.]]></category>
		<category><![CDATA[VRSN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82981</guid>
		<description><![CDATA[•    Ulta Salon, Cosmetics &#38; Fragrance, Inc. (NASDAQ:ULTA) posted second quarter 2011 earnings of $0.38 per share, which surpassed the Zacks Consensus Estimate of $0.32 •    VeriSign Inc. (NASDAQ:VRSN) announced the resignation of its Chief Financial Officer Brian Robins, who stepped down to move on to other opportunities •    The Kroger Co. (NYSE:KR) posted second-quarter 2011 earnings of $0.41 per share, below the Zacks Consensus Estimate of $0.43 per share •    According to reports from The Wall Street Journal, Bank of America Corporation (NYSE:BAC) is planning to lay off roughly 40,000 employees •    Ticonderoga Securities downgraded Lazard Ltd. (NYSE:LAZ) to “Neutral” from a “Buy” rating •    Credit Suisse downgraded Sanofi-Aventis (NYSE:SNY) to “Neutral” from an “Outperform” rating •    Bank of America Corporation downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to “Underperform” from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/12/bac-company-news-for-september-12-2011-corporate-summary/82981/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322</link>
		<comments>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82322</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s second quarter 2011 loss of 33 cents per share was narrower than the Zacks Consensus Estimate of a loss of 37 cents per share and the year-ago loss of 35 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. Revenues for the reported quarter fell 22.6% from the prior year to $20.6 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Loss Less Than Analyst Estimates &#8211; Revenues Rise</title>
		<link>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906</link>
		<comments>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:31:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80906</guid>
		<description><![CDATA[Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting for the change in fair value of warrants). The loss was, however, narrower than the Zacks Consensus Estimate of a loss of 21 cents due to higher-than-expected revenues. Loss widened from the prior year due to higher operating expenses which more than offset the rise in revenues. Quarterly Details Revenues at Micromet were up 7.8% to $7.1 million in the second quarter of 2011 on the back of higher collaboration revenue. Revenues were also above the Zacks Consensus Estimate of $6 million. Operating expenses during the reported quarter climbed approximately 56% over the prior-year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals International Beats Expectations &#8211; Ups View</title>
		<link>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862</link>
		<comments>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862#comments</comments>
		<pubDate>Mon, 08 Aug 2011 17:31:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Cogdell Spencer Inc.]]></category>
		<category><![CDATA[CSA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80862</guid>
		<description><![CDATA[Valeant Pharmaceuticals International’s (VRX) second quarter 2011 earnings of 68 cents per share (excluding special items but including stock based compensation expense) beat the Zacks Consensus Estimate by 3 cents and the year-ago earnings by 8 cents per share. Bottom-line growth was driven by improved revenues. Adjusted diluted earnings, however, included an extraordinary gain of 6 cents from the sale of investment in Cephalon Inc. (CEPH). Revenues for the quarter were $609.4 million, marginally above the Zacks Consensus Estimate of $609 million and way ahead of the prior-year figure of $238.8 million. However, revenue included a one-time milestone payment of $40 million received from GlaxoSmithkline (GSK) related to the European launch of Trobalt (known as Potiga in the US). The improvement in revenues was primarily due to the September 2010 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Reports Solid Quarter</title>
		<link>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092</link>
		<comments>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092#comments</comments>
		<pubDate>Wed, 03 Aug 2011 19:53:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80092</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues boosted earnings in the reported quarter. On a reported basis (including special items), Bristol-Myers’ earnings in the quarter decreased 2% to $0.52 per share. The healthcare reform enacted in 2010 negatively impacted earnings in the reported quarter by $0.03. Net sales in the reported quarter climbed 14% to $5.4 billion. Foreign exchange positively impacted sales in the quarter by 4%. Revenues also surpassed the Zacks Consensus Estimate of $5.0 billion, driven by the impressive showing of Bristol-Myers’ lead drugs including blood thinner Plavix. US net sales in the quarter climbed 15% to $3.6 billion. Sales in international markets increased 13% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(REGN) Regeneron Pharmaceuticals Gets Mixed Data for REGN88</title>
		<link>http://www.stockbloghub.com/2011/07/14/regn-regeneron-pharmaceuticals-gets-mixed-data-for-regn88/79111</link>
		<comments>http://www.stockbloghub.com/2011/07/14/regn-regeneron-pharmaceuticals-gets-mixed-data-for-regn88/79111#comments</comments>
		<pubDate>Thu, 14 Jul 2011 21:30:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Minerals Technologies Inc.]]></category>
		<category><![CDATA[MTX]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79111</guid>
		<description><![CDATA[Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi Aventis (SNY) recently announced data from two mid-stage studies of their pipeline candidate sarilumab (REGN88/SAR153191). While one study (MOBILITY) evaluated patients with rheumatoid arthritis (RA) the other (ALIGN) evaluated ankylosing spondylitis (AS) patients. Sarilumab is an antibody targeting the interleukin-6 receptor (IL-6R). The data from the RA trial was positive while the AS trial data was not too encouraging. The MOBILITY (n=306) trial showed that sarilumab in combination with methotrexate (MTX), the standard of care for RA, led to significant improvement in signs and symptoms of moderate-to-severe RA patients versus patients treated with MTX plus placebo. The trial compared 5 doses of sarilumab plus MTX to placebo plus MTX. 49% of patients receiving the lowest dose met the primary endpoint of at least ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/regn-regeneron-pharmaceuticals-gets-mixed-data-for-regn88/79111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Downgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/10/prgo-perrigo-downgraded-to-neutral/78723</link>
		<comments>http://www.stockbloghub.com/2011/07/10/prgo-perrigo-downgraded-to-neutral/78723#comments</comments>
		<pubDate>Mon, 11 Jul 2011 05:36:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78723</guid>
		<description><![CDATA[We recently moved to a Neutral rating on Perrigo Company (PRGO) from Outperform. Our target price on the stock is $94.00. Perrigo’s broad line of store brand pharmaceutical products has the same active ingredients and comparable quality and efficacy as the national brands. This has helped the company become a dominant player in the store brand over the counter (OTC) drug market. We believe that Perrigo’s strong position in the brand OTC pharmaceutical market, and growing generics and API businesses will help it deliver solid top- and bottom-line growth in the coming years. In the OTC pharmaceutical market, some products are sold due to changes in product status from prescription (Rx) only to non-prescription (OTC). This process is called Rx-to-OTC switch and it requires FDA approval. Management estimates that $10 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/10/prgo-perrigo-downgraded-to-neutral/78723/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Analyst Maintains Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351</link>
		<comments>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351#comments</comments>
		<pubDate>Wed, 06 Jul 2011 00:16:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78351</guid>
		<description><![CDATA[We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (OPTR) with a target price of $12.00 per share. We find the US Food and Drug Administration’s (FDA) approval of Optimer’s first drug, antibiotic Dificid, for the treatment of clostridium difficile-associated diarrhea (CDAD), highly encouraging. CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. Dificid (twice daily tablets) is the first drug to be approved in almost 30 years for the treatment of CDAD. Dificid is the only drug which has shown superiority over ViroPharma’s (VPHM) Vancocin &#8211; the only other FDA approved antibiotic for the treatment of clostridium difficile infection &#8211; in sustaining clinical response for CDAD. The superior recurring benefits of Dificid over Vancocin will be included ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Boost for Bayer and Johnson &amp; Johnson</title>
		<link>http://www.stockbloghub.com/2011/07/05/jnj-boost-for-bayer-and-johnson-johnson/78369</link>
		<comments>http://www.stockbloghub.com/2011/07/05/jnj-boost-for-bayer-and-johnson-johnson/78369#comments</comments>
		<pubDate>Wed, 06 Jul 2011 00:07:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78369</guid>
		<description><![CDATA[Recently, the US Food and Drug Administration (FDA) delivered a huge boost for Bayer (BAYRY) and partner Johnson &#38; Johnson (JNJ) by clearing their blood-thinner (anticoagulant) Xarelto (rivaroxaban). The US regulatory body cleared the drug, which has blockbuster potential, for the prevention of deep vein thrombosis (DVT) which may cause pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery.  The blood-thinner is already available in Europe for the indication. The current approval will allow Xarelto to be marketed in the US as a once-daily tablet (10 mg). The tablet is to be taken for 35 days after hip replacement and for 12 days after knee replacement. The US approval was based on late-stage studies which showed that Xarelto was more effective than Sanofi-Aventis’ (SNY) Lovenox (enoxaparin). Moreover, Xarelto ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/jnj-boost-for-bayer-and-johnson-johnson/78369/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Presents Late Stage Degludec Data</title>
		<link>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249</link>
		<comments>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:06:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78249</guid>
		<description><![CDATA[Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia (low blood sugar) versus Sanofi Aventis’(SNY) Lantus in patients with type II diabetes. Novo Nordisk presented data from two, late stage, 52-week clinical trials, one in patients with type I and the other in victims of type II diabetes. These data were presented at the American Diabetes Association. Degludec particularly reduced nocturnal hypoglycemia (night-time episodes of excessively low blood sugar) versus Lantus in patients with type I or type II diabetes. Nocturnal hypoglycemia is highly feared by diabetics, and hence a reduced threat of it represents a real commercial edge for Degludec. Apart from the two studies, Novo Nordisk also presented data ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Expands HIV Drug&#8217;s Reach</title>
		<link>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060</link>
		<comments>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060#comments</comments>
		<pubDate>Thu, 30 Jun 2011 20:41:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78060</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Mylan Inc. (MYL) to expand the market for its HIV drug Reyataz (atazanavir sulfate). The deal allows Matrix to develop and sell the generic version of the HIV therapy in the Indian and sub-Saharan African markets. Apart from Reyataz, Mylan will also sell the generic versions of other Bristol-Myers HIV therapies such as Videx (didanosine) and Zerit (stavudine) in the above territories as per the agreement. The transaction marks the fifteenth deal signed by Bristol-Myers in the field of HIV and the fourth deal involving Reyataz. The deal also promises the pediatric versions of the HIV therapies. The deal permits Mylan’s Matrix Laboratories to secure prequalification from the World Health Organization (WHO) for all the offerings covered by the deal. This ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs and Reata Pharmaceuticals Present New Phase II Data</title>
		<link>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768</link>
		<comments>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:43:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Marshall & Ilsley Corporation]]></category>
		<category><![CDATA[MI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77768</guid>
		<description><![CDATA[Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently announced the presentation of new phase II data on bardoxolone methyl. In addition to being posted online in The New England Journal of Medicine, the data were also presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress. The phase II BEAM study was conducted in patients with moderate to severe chronic kidney disease and type II diabetes. Results showed that patients receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period as measured by estimated glomerular filtration rate (eGFR), which is an important measure of kidney function. All three doses (25, 75 or 150 mg) of bardoxolone methyl achieved a statistically significant improvement in eGFR compared to placebo. Moreover, only 9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MHS) Medco Health Solutions Aids Sanofi-Aventis Study</title>
		<link>http://www.stockbloghub.com/2011/06/28/mhs-medco-health-solutions-aids-sanofi-aventis-study/77737</link>
		<comments>http://www.stockbloghub.com/2011/06/28/mhs-medco-health-solutions-aids-sanofi-aventis-study/77737#comments</comments>
		<pubDate>Tue, 28 Jun 2011 23:31:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[E-TRACS UBS Bloomberg CMCI Livestock ETN]]></category>
		<category><![CDATA[FEP]]></category>
		<category><![CDATA[Franklin Electronic Publishers Inc]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[UBC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77737</guid>
		<description><![CDATA[Medco Health Solutions (MHS) and its subsidiary United BioSource Corporation (UBC) have entered into a multi-year agreement with leading pharmaceutical company Sanofi-Aventis (SNY). Under the agreement, Medco would provide real-world evidence assessments during the product’s development by Sanofi-Aventis. Financial terms of the deal were not disclosed. Following this agreement, Sanofi-Aventis would be better placed to identify patients with huge unmet medical needs. Furthermore, the companies will strive to trace out patients on whom the drugs are most effective and also generate real-world comparative effectiveness data. This is significant as some products that hold promise in early research does not deliver expected results when applied. Medco Health has been recording increase in revenues from services primarily driven by the UBC acquisition. The acquisition provides encouraging results for the company with more ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/mhs-medco-health-solutions-aids-sanofi-aventis-study/77737/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire to Produce More Replagal</title>
		<link>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664</link>
		<comments>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664#comments</comments>
		<pubDate>Tue, 28 Jun 2011 15:54:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HGT]]></category>
		<category><![CDATA[Hugoton Royalty Trust]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77664</guid>
		<description><![CDATA[UK-based Shire (SHPGY) recently announced that the European Medicines Agency (EMA) has increased the company’s manufacturing flexibility for Replagal (agalsidase alfa), an enzyme replacement therapy approved for treating Fabry disease. The EMA declared that Replagal can be purified at its new manufacturing facility located in Lexington. The European approval for the new manufacturing facility for Replagal was sought by Shire in April 2011. The approval grants Shire, the global market leader for the treatment of Fabry disease, an additional manufacturing facility to purify the product. Prior to the approval, Replagal was purified only at the company’s facility in Alewife, Cambridge. The increased manufacturing strength will enable Shire meet the huge demand for treating the disease in a more efficient manner. Shire’s Replagal competes with Sanofi-Aventis’ (SNY) Fabrazyme in the market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug</title>
		<link>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318</link>
		<comments>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:18:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77318</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner apixaban in patients suffering from an erratic heartbeat. This cardiac rhythm disorder is referred to as atrial fibrillation (AF). Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US and other countries. Top-line results from the double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin with respect to the combined outcome of stroke and systemic embolism. Data further revealed that Eliquis was superior to warfarin with respect to effectiveness and major bleeding. Bristol-Myers and Pfizer intend to seek approval from the US Food and Drug Administration (FDA) and also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Analyst Mintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315</link>
		<comments>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:03:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77315</guid>
		<description><![CDATA[We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25. Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for cancer. The company’s lead pipeline candidate, pixantrone, is being developed for the treatment of hematologic malignancies and solid tumors. In December 2010, Cell Therapeutics filed an appeal against the decision of the FDA in April 2010 to deny approval to pixantrone for the treatment of relapsed, aggressive non-Hodgkin&#8217;s lymphoma, or NHL, in patients who have not responded to other treatment options. The approval was denied due to concerns that the late stage trial PIX301 (which formed the basis of the NDA filing) had not sufficiently proved the effectiveness of the drug. The FDA asked Cell Therapeutics to conduct an additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291</link>
		<comments>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291#comments</comments>
		<pubDate>Thu, 23 Jun 2011 19:34:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77291</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s first quarter loss of 38 cents per share was wider than the Zacks Consensus Estimate of 32 cents per share and also the year-ago loss of 29 cents. Lower revenues and higher research and development expenses led to the greater loss. Revenues for the reported quarter fell 15% from the prior year to $20.9 million but were in line with the Zacks Consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs&#8217; Bardoxolone in Phase III Trials</title>
		<link>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721</link>
		<comments>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:25:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Marshall & Ilsley Corporation]]></category>
		<category><![CDATA[MI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76721</guid>
		<description><![CDATA[Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently commenced a pivotal phase III study with bardoxolone methyl. Bardoxolone methyl’s safety and efficacy will be evaluated in patients with chronic kidney disease and type II diabetes. Study Design The multinational, double-blind, placebo-controlled phase III study, BEACON (Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes: the Occurrence of renal eveNts), will be conducted with about 1,600 patients across 300 sites. Patients will be randomized 1:1 to receive either a 20 mg reformulated version of bardoxolone methyl or placebo once daily. While the primary efficacy endpoint is a time-to-first-event composite consisting of progression to end-stage renal disease (ESRD) and cardiovascular death, secondary endpoints include change in estimated glomerular filtration rate (eGFR) and a time-to-first-event composite consisting of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Set to Resubmit Pixantrone NDA</title>
		<link>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603</link>
		<comments>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:50:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76603</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) recently met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration (FDA) and received guidance for resubmission of the new drug application (NDA) for its lead pipeline candidate pixantrone. Pixantrone has been developed for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. The company is also looking for accelerated approval of the NDA based on data from the PIX301 study. The meeting follows the early May decision of the Office of New Drugs (OND) of the FDA allowing the company to re-submit the NDA for pixantrone for review without the need for an additional trial. The OND recommended Cell Therapeutics to conduct an additional independent radiologic review utilizing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Gets Another Feather in its Cap</title>
		<link>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633</link>
		<comments>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:42:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76633</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) product portfolio was boosted further when the US Food and Drug Administration (FDA) approved its drug Nulojix (belatacept) to prevent the rejection of transplanted kidneys in adults. We remind investors that Bristol-Myers has succeeded in getting the drug approved in the US for the indication in its second attempt. In the second quarter of 2010, the FDA issued a complete response letter in response to biologic license application (BLA) submitted by the pharma major for Nulojix , asking for additional information. Subsequently, Bristol-Myers submitted it. In December 2010, the agency had thereby announced that it would review the re-submitted application by June 15, 2011 (action date). The agency cleared the drug following the review thereby delivering a further boost to the company. We note that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Compan Gets Good News</title>
		<link>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752</link>
		<comments>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752#comments</comments>
		<pubDate>Wed, 15 Jun 2011 16:49:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74752</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (BMY) received a boost when its blood-thinner Eliquis (apixaban) was cleared by the European Commission (EC) in 27 nations of the European Union (EU) for preventing venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery. The approval by the EC is the first approval for Eliquis, a new oral direct factor Xa inhibitor. Bristol-Myers has co-developed the drug with Pfizer (PFE). The approval was based on ADVANCE-2 and ADVANCE-3 studies which revealed that the drug was statistically superior to 40 mg once-daily Lovenox (enoxaparin) of Sanofi-Aventis (SNY) without increase in bleeding rates. The decision of the EC to approve Eliquis does not surprise us since the drug had won a positive recommendation from the Committee for Medicinal Products for Human Use ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MAA) Roche Holdings&#8217; Skin Cancer Drug Impresses</title>
		<link>http://www.stockbloghub.com/2011/06/12/maa-roche-holdings-skin-cancer-drug-impresses/75908</link>
		<comments>http://www.stockbloghub.com/2011/06/12/maa-roche-holdings-skin-cancer-drug-impresses/75908#comments</comments>
		<pubDate>Sun, 12 Jun 2011 17:14:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75908</guid>
		<description><![CDATA[Roche Holdings Ltd. (RHHBY) recently presented encouraging data from a phase III trial (BRIM 3) on BRAF V600 mutation-positive metastatic melanoma candidate, vemurafenib (RG7204, PLX4032), at the annual meeting of the American Society of Clinical Oncology (ASCO). The BRIM 3 study was conducted to compare vemurafenib with dacarbazine (chemotherapy) in patients with previously untreated BRAF V600 mutation-positive, unresected, locally advanced or metastatic melanoma (skin cancer). Upon comparison with chemotherapy, the study results demonstrated that patients on vemurafenib experienced a significant improvement in overall survival, with the risk of death reducing by 63%. The study also met the co-primary endpoint of reducing the risk of disease aggravation by 74% compared with chemotherapy. Last month, Roche submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/12/maa-roche-holdings-skin-cancer-drug-impresses/75908/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RCI) Look to Dividends for Income</title>
		<link>http://www.stockbloghub.com/2011/06/09/rci-look-to-dividends-for-income/75257</link>
		<comments>http://www.stockbloghub.com/2011/06/09/rci-look-to-dividends-for-income/75257#comments</comments>
		<pubDate>Thu, 09 Jun 2011 17:39:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Broadcasting - TV]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AHGP]]></category>
		<category><![CDATA[Alliance Holdings Gp L.P.]]></category>
		<category><![CDATA[Alliance Resource Partners LP]]></category>
		<category><![CDATA[ARLP]]></category>
		<category><![CDATA[AVA]]></category>
		<category><![CDATA[Avista Corporation]]></category>
		<category><![CDATA[BCE]]></category>
		<category><![CDATA[BCE Inc.]]></category>
		<category><![CDATA[National Bankshares Inc]]></category>
		<category><![CDATA[NKSH]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[RCI]]></category>
		<category><![CDATA[Rogers Communications Inc.]]></category>
		<category><![CDATA[RPM]]></category>
		<category><![CDATA[RPM International Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TELUS Corporation]]></category>
		<category><![CDATA[TMP]]></category>
		<category><![CDATA[Tompkins Financial Corporation.]]></category>
		<category><![CDATA[TU]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75257</guid>
		<description><![CDATA[With the 10-year T-note yielding only 3.06%, those investors interested in getting income from their investments are in sort of a tough place. Dividend-paying stocks are a very good place to look for a replacement. One thing you know for sure is that the coupon payment on a 10-year note is not going to rise. A yield of 3.06% does not offer much of a cushion against inflation. What is inflation likely to average over the next 10 years? I have no idea, but based on the spread between the regular 10-year note, and the 10-year TIPS, the market is implicitly expecting a rate of about 2.50%, which is pretty much in line with the historical experience (Headline CPI) over the last 20 years of 2.57%. While core inflation is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/09/rci-look-to-dividends-for-income/75257/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharma Beats on One-Time Gain</title>
		<link>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730</link>
		<comments>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730#comments</comments>
		<pubDate>Wed, 11 May 2011 05:28:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73730</guid>
		<description><![CDATA[Optimer Pharma’s (OPTR) first quarter 2011 earnings of $1.14 per share tellingly reversed the year-ago loss of 39 cents per share and exceeded the Zacks Consensus Estimate of 30 cents. The earnings beat was due to a huge increase in the top-line in the reported quarter. In the first quarter, revenues were $69.3 million versus $0.30 million in the prior-year quarter. Optimer does not have any marketed products at present. The substantial year-over-year growth was due to the receipt of a one-time $69.2 million upfront payment from Astellas Pharma in exchange for development and commercialization rights for fidaxomicin in certain territories outside US. Fidaxomicin is Optimer’s primary drug candidate which is currently under review both in the US and Europe for the treatment of Clostridium difficile infection (CDI). Fidaxomicin will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reported Loss Widens</title>
		<link>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669</link>
		<comments>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669#comments</comments>
		<pubDate>Mon, 09 May 2011 21:33:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73669</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents. Revenues came in at $21.1 million, well below the Zacks Consensus Estimate of $26 million. Lower revenues and higher operating expenses led to the wider first quarter 2011 loss. Quarter in Detail Revenues, which include license fees, milestone-related payments and other payments, declined 29.3% from the year-ago period during the first quarter of 2011. Isis Pharma earned a $750,000 milestone payment from OncoGenex (OGXI) on the initiation of a phase II study with OGX-427. First quarter revenues also included revenues recognized under the company’s collaboration agreement with GlaxoSmithKline (GSK). Isis Pharma could receive another ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Cruises Past Estimates &#8211; Lifts Outlook</title>
		<link>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520</link>
		<comments>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520#comments</comments>
		<pubDate>Sun, 08 May 2011 15:51:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73520</guid>
		<description><![CDATA[Perrigo Company (PRGO) reported earnings per share of $1.07 for the third quarter of fiscal 2011, easily beating the Zacks Consensus Estimate of 96 cents and the year-earlier earnings of 81 cents per share. Results were driven by a solid top-line performance. Third quarter revenues increased 29% over the prior year to $692 million. Total revenues were also above the Zacks Consensus Estimate of $686 million. The year-over-year revenue growth was boosted by strong performances by the company’s generic prescription and active pharmaceutical ingredient (API) businesses. New products added $44 million to revenues. The Quarter in Detail The revenue performance in the quarter from four of the company’s businesses is detailed below. Consumer Healthcare (CHC): Perrigo reported CHC revenue of $425 million in the third quarter, up 13% over the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Earnings Beat The Street &#8211; Backs Outlook</title>
		<link>http://www.stockbloghub.com/2011/05/03/hsp-hospira-earnings-beat-the-street-backs-outlook/72495</link>
		<comments>http://www.stockbloghub.com/2011/05/03/hsp-hospira-earnings-beat-the-street-backs-outlook/72495#comments</comments>
		<pubDate>Tue, 03 May 2011 19:27:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[APAC]]></category>
		<category><![CDATA[APAC Customer Services Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MAXIMUS Inc.]]></category>
		<category><![CDATA[MMS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72495</guid>
		<description><![CDATA[Hospira Inc. (HSP) reported earnings per share of 93 cents for the first quarter of 2011, well above the Zacks Consensus Estimate of 79 cents. Earnings benefited from strong US sales of the generic version of Sanofi Aventis’ (SNY) cancer drug Taxotere which was launched in March 2011. Results were however 1 cent below the year-earlier earnings of 94 cents due to difficult year-over-year comparisons. Earnings in the prior-year quarter were boosted by strong margin contribution from US sales of Hospira’s generic version of Sanofi’s Eloxatin (oxaliplatin) which has been temporarily discontinued. Higher research and development expenses also affected earnings in the quarter. First quarter revenues of $1 billion were almost flat year over year. Total revenues beat the Zacks Consensus Estimate of $941 million. The top line was boosted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/hsp-hospira-earnings-beat-the-street-backs-outlook/72495/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Posts Solid First Quarter Sales</title>
		<link>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906</link>
		<comments>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:54:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71906</guid>
		<description><![CDATA[Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from the base period resulted from financing costs for the Alcon acquisition completed in April this year. An increase in the number of shares outstanding, in the quarter, following dilution from the merger also affected earnings. Also marring earnings were robust profits booked in 2009 from windfall sales of H1N1 flu vaccines that were not to be repeated in the current quarter. First quarter revenues were up a solid 16% over the prior year to $14.0 billion. Total revenues also edged past the Zacks Consensus Estimate of $13.4 billion, driven by strong performance of newly launched ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Five Large Cap Pharmaceuticals to Consider</title>
		<link>http://www.stockbloghub.com/2011/04/27/mrk-five-large-cap-pharmaceuticals-to-consider/72522</link>
		<comments>http://www.stockbloghub.com/2011/04/27/mrk-five-large-cap-pharmaceuticals-to-consider/72522#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:41:27 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72522</guid>
		<description><![CDATA[The Large Cap Pharma sector is the fastest rising sector on Barchart when screening for the 1 month price change.  The general investing public is very interested in this sector as evidenced by the 25,409 opinions expressed on Motley Fool on the 5 stocks I selected.  Before buying make sure a pharma fits into your asset allocation plan and then please do you own further due diligence.  Read my opinion at the end of this article.  Let&#8217;s look at these 5. Merck (MRK) &#8211;  a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/mrk-five-large-cap-pharmaceuticals-to-consider/72522/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Idec Earnings Above Estimates on Multiple Sclerosis Drugs</title>
		<link>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234</link>
		<comments>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234#comments</comments>
		<pubDate>Tue, 26 Apr 2011 15:42:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72234</guid>
		<description><![CDATA[Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per share. Performance was boosted by higher multiple sclerosis (MS) drug revenues, lower costs and lower share count. Biogen has been looking to streamline its operations and increase efficiencies through the implementation of a restructuring program. The company’s restructuring program includes initiatives like streamlining of operations, shutting down of facilities, and workforce reduction. Biogen is also focusing its development efforts on neurology and biologics. First quarter revenues increased 9% to $1.20 billion, with MS drugs, Tysabri and Avonex being the primary growth drivers. Revenues were above the Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/26/biib-biogen-idec-earnings-above-estimates-on-multiple-sclerosis-drugs/72234/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

